BioSpace Collaborative - IL-2 Stimulated but Not Unstimulated NK Cells Induce Selective Disappearance of Peripheral Blood Cells: Concomitant Results to a Phase I/II Study

Academic/Biomedical Research
News & Jobs

Employers
Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

PLoS By Category | Recent PLoS Articles

Hematology - Immunology - Oncology - Pediatrics and Child Health

IL-2 Stimulated but Not Unstimulated NK Cells Induce Selective Disappearance of Peripheral Blood Cells: Concomitant Results to a Phase I/II Study
Published: Wednesday, November 09, 2011
Author: Claudia Brehm et al.

by Claudia Brehm, Sabine Huenecke, Andrea Quaiser, Ruth Esser, Melanie Bremm, Stephan Kloess, Jan Soerensen, Hermann Kreyenberg, Christian Seidl, Petra S. A. Becker, Heiko Mühl, Thomas Klingebiel, Peter Bader, Jakob R. Passweg, Dirk Schwabe, Ulrike Koehl

In an ongoing clinical phase I/II study, 16 pediatric patients suffering from high risk leukemia/tumors received highly purified donor natural killer (NK) cell immunotherapy (NK-DLI) at day (+3) +40 and +100 post haploidentical stem cell transplantation. However, literature about the influence of NK-DLI on recipient's immune system is scarce. Here we present concomitant results of a noninvasive in vivo monitoring approach of recipient's peripheral blood (PB) cells after transfer of either unstimulated (NK-DLI_(unstim)) or IL-2 (1000 U/ml, 9–14 days) activated NK cells (NK-DLI_{(IL-2 stim)}) along with their ex vivo secreted cytokine/chemokines. We performed phenotypical and functional characterizations of the NK-DLIs, detailed flow cytometric analyses of various PB cells and comprehensive cytokine/chemokine arrays before and after NK-DLI. Patients of both groups were comparable with regard to remission status, immune reconstitution, donor chimerism, KIR mismatching, stem cell and NK-DLI dose. Only after NK-DLI_{(IL-2 stim)} was a rapid, almost complete loss of CD56^(bright)CD16^(dim/-) immune regulatory and CD56^(dim)CD16⁽⁺⁾ cytotoxic NK cells, monocytes, dendritic cells and eosinophils from PB circulation seen 10 min after infusion, while neutrophils significantly increased. The reduction of NK cells was due to both, a decrease in patients' own CD69^(-) NCR^(low)CD62L⁽⁺⁾ NK cells as well as to a diminishing of the transferred cells from the NK-DLI_{(IL-2 stim)} with the CD56^(bright)CD16^(+/-)CD69⁽⁺⁾NCR^(high)CD62L^(-) phenotype. All cell counts recovered within the next 24 h. Transfer of NK-DLI_{(IL-2 stim)} translated into significantly increased levels of various cytokines/chemokines (i.e. IFN-?, IL-6, MIP-1ß) in patients' PB. Those remained stable for at least 1 h, presumably leading to endothelial activation, leukocyte adhesion and/or extravasation. In contrast, NK-DLI_(unstim) did not cause any of the observed effects. In conclusion, we assume that the adoptive transfer of NK-DLI_{(IL-2 stim)} under the influence of ex vivo and in vivo secreted cytokines/chemokines may promote NK cell trafficking and therefore might enhance efficacy of immunotherapy. More...